Literature DB >> 30763188

Residual Disease after Neoadjuvant Therapy - Developing Drugs for High-Risk Early Breast Cancer.

Tatiana M Prowell1, Julia A Beaver1, Richard Pazdur1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30763188     DOI： 10.1056/NEJMp1900079

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  10 in total

Review 1.  Neoadjuvant checkpoint blockade for cancer immunotherapy.

Authors:  Suzanne L Topalian; Janis M Taube; Drew M Pardoll
Journal:  Science       Date:  2020-01-31       Impact factor: 47.728

2.  Neoadjuvant dual anti-HER2 therapy for early breast cancer: where do we stand?

Authors:  Pankaj G Roy; Didier Verhoeven
Journal:  Gland Surg       Date:  2020-10

Review 3.  U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.

Authors:  Shaily Arora; Preeti Narayan; Christy L Osgood; Suparna Wedam; Tatiana M Prowell; Jennifer J Gao; Mirat Shah; Danielle Krol; Sakar Wahby; Melanie Royce; Soma Ghosh; Reena Philip; Gwynn Ison; Tara Berman; Christina Brus; Erik W Bloomquist; Mallorie H Fiero; Shenghui Tang; Richard Pazdur; Amna Ibrahim; Laleh Amiri-Kordestani; Julia A Beaver
Journal:  Clin Cancer Res       Date:  2022-03-15       Impact factor: 13.801

4.  HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment.

Authors:  Federica Miglietta; Gaia Griguolo; Michele Bottosso; Tommaso Giarratano; Marcello Lo Mele; Matteo Fassan; Matilde Cacciatore; Elisa Genovesi; Debora De Bartolo; Grazia Vernaci; Ottavia Amato; Francesca Porra; PierFranco Conte; Valentina Guarneri; Maria Vittoria Dieci
Journal:  NPJ Breast Cancer       Date:  2022-05-20

Review 5.  Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop.

Authors:  Chana Weinstock; Matthew D Galsky; Elaine Chang; Andrea B Apolo; Rick Bangs; Stephanie Chisolm; Vinay Duddalwar; Jason A Efstathiou; Kirsten B Goldberg; Donna E Hansel; Ashish M Kamat; Paul G Kluetz; Seth P Lerner; Elizabeth Plimack; Tatiana Prowell; Harpreet Singh; Daniel Suzman; Evan Y Yu; Hui Zhang; Julia A Beaver; Richard Pazdur
Journal:  Nat Rev Urol       Date:  2021-09-10       Impact factor: 14.432

Review 6.  Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications.

Authors:  Maria Vittoria Dieci; Federica Miglietta; Valentina Guarneri
Journal:  Cells       Date:  2021-01-23       Impact factor: 6.600

7.  Unmet challenges in systemic therapy for early stage breast cancer.

Authors:  Harold J Burstein
Journal:  Breast       Date:  2021-12-13       Impact factor: 4.254

Review 8.  An overview of immune checkpoint inhibitors in breast cancer.

Authors:  Federica Miglietta; Maria Silvia Cona; Maria Vittoria Dieci; Valentina Guarneri; Nicla La Verde
Journal:  Explor Target Antitumor Ther       Date:  2020-12-28

9.  Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer.

Authors:  Gagan Gupta; Caroline Dasom Lee; Mary L Guye; Robert E Van Sciver; Michael P Lee; Alex C Lafever; Anthony Pang; Angela M Tang-Tan; Janet S Winston; Billur Samli; Rick J Jansen; Richard A Hoefer; Amy H Tang
Journal:  Ann Breast Cancer Ther       Date:  2020-05-02

10.  Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.

Authors:  Qigu Yao; Lihu Gu; Rong Su; Bangsheng Chen; Hongcui Cao
Journal:  J Cell Mol Med       Date:  2020-10-20       Impact factor: 5.295
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.